The objective is to produce anti-herpes simplex virus type 1 (HSV-1) peptide pharmaceuticals that lock entry of HSV-1 into target cells. Preliminary data have identified several putative lead peptides, but using viral mutagenesis, synthesis of overlapping peptides from each of four HSV-1 surface glycoproteins, a set of lead peptides will results. The latter will be modified by modern peptide pharmaceutical procedures to improve their "activity-stability-delivery" profiles. Both in vitro and in vivo assays will be used to rank activity of these modified peptides. It is proposed natural and modified anti-herpes peptides will be used alone or in combination with nucleoside anti-herpes pharmaceuticals to reduce infection times, overcome resistant strains and alleviate the more severe HSV-1 symptoms such as pain, blindness and herpes encephalitis.
Funding SchemeCSC - Cost-sharing contracts
CB2 1QP Cambridge